

Lab Resource: Stem Cell Line

Derivation of human embryonic stem cell line Genea023

Biljana Dumevska ^{*,1}, Alexis Bosman ¹, Robert McKernan, Divya Goel, Uli Schmidt, Teija Peura

Genea Biocells, Sydney, Australia

ARTICLE INFO

Article history:

Received 26 January 2016

Accepted 1 February 2016

Available online 3 February 2016

ABSTRACT

The Genea023 human embryonic stem cell line was derived from a donated, fully commercially consented ART blastocyst, through ICM outgrowth on inactivated feeders. The line showed pluripotent cell morphology and genomic analysis verified a 46, XY karyotype and male allele pattern through CGH and STR analysis. Pluripotency of Genea023 was demonstrated with 85% of cells expressed Nanog, 98% Oct4, 55% Tra1-60 and 98% SSEA4, gave a Pluritest Pluripotency score of 42.76, Novelty of 1.23, demonstrated Alkaline Phosphatase activity and tri-lineage teratoma formation. The cell line was negative for *Mycoplasma* and visible contamination.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Resource table

Name of stem cell line	Genea023 (alternate ID: SIVF023)
Institution	Genea Biocells
Person who created resource	Alexis Bosman
Contact person and email	biljana.dumevska@geneabiocells.com
Date archived/stock date	December, 2005
Origin	Human embryos
Type of resource	Derived human embryonic stem cell line
Sub-type	Human pluripotent cell line
Key marker expression	Nanog, Oct4, Tra1-60, and SSEA4
Authentication	Identity and purity of cell line confirmed (Figs. 1–2 and Tables 1–3 below)
Link to related literature (direct URL links and full references)	(Laurent et al., 2010) http://www.ncbi.nlm.nih.gov/pubmed/?term=20038950 (Laurent et al., 2011) http://www.ncbi.nlm.nih.gov/pubmed/?term=21211785 (McQuade et al., 2014) http://www.ncbi.nlm.nih.gov/pubmed/25316320 (Bosman et al., 2015) http://www.ncbi.nlm.nih.gov/pubmed/25645121
Information in public databases	UK Stem Cell Bank registered, UKSCB: SCS14-60 SNP Data Gene Expression Omnibus accession number, GEO: GSM638435

Resource details

Date of derivation	December 2004
Karyotype	46, XY — hemizygous loss of approximately 735 kb on chromosome 1
Sex	Male
Pluripotent	YES — by Nanog, Oct4, Tra1-60, and SSEA4 staining, Pluritest and Alkaline Phosphatase
Disease status	Unaffected
Sterility	The cell line is tested and found negative for <i>Mycoplasma</i> and any visible contamination
Sibling lines available	YES — Genea021 (XY, TS21 affected — UKSCB: SCS14-60), Genea022 (XY, UKSCB: SCS14-60)

Materials and methods

Cell line derivation

A fresh, blastocyst stage embryo was bisected and plated onto Mitomycin C inactivated human feeders (Detroit 551 HFF — 130,000/well in 4-well) in 20% KSR medium (Amit et al., 2000) with 50 ng/mL FGF added fresh. CGH karyotyping and STR profiling was performed at the first cryobanking step from ICM outgrowths maintained on feeders. Alkaline Phosphatase staining and teratoma formation was performed from feeders. Cells were then enzymatically passaged as single cells in M2 pluripotent cell maintenance medium (Genea Biocells) and CGH/karyotyping repeated, immunofluorescent pluripotent marker staining, pluritest and sterility testing performed.

* Corresponding author.

E-mail address: biljana.dumevska@geneabiocells.com (B. Dumevska).¹ Equal contributions.




Fig. 1. Morphology and karyotype of Genea023. A) Alkaline Phosphatase activity (passage 14) on human inactivated feeders. B) Karyotypic analysis (passage 38) showing 46, XY normal, male karyotype.

Table 1

CGH analysis summary; Genea023 (passage 15, 4 enzymatic) reporting a male cell line with hemizygous loss of approximately 735 kb on chromosome 1.

CGH summary	
Sample name	Genea023p15_TE4
Date reported	8th October 2012
Hybridisation balance	Balanced hybridization was observed for chromosomes 2–22 and sex chromosomes, relative to reference DNA Unbalanced hybridization was observed for chromosome 1
Copy number change	Loss, 1q21.2 approximately 735 kb
Interpretation	Male cell line – a hemizygous loss of approximately 735 kb on chromosome 1

Genetic analysis

- Karyotyping:** Passage 38; For enrichment of metaphase cells, cellular outgrowths were incubated with either 0.22 ng/mL colcemid (Invitrogen) and 37.5 g/mL BrdU (Sigma) for 17–19 h or 5 ng/mL colcemid for 2.5 h. Single cells were subsequently obtained using Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory for preparation of metaphase spreads and cytogenetic analysis by G-banding. A minimum of 15 metaphase cells were examined, of which a full karyotype or chromosome count was performed for 5 and 10 of the metaphases respectively.

Table 2

STR profile; Genea023 (passage 8) demonstrating male allele pattern.

	D8S1179	D21S11	D7S820	CSF1PO	D3S1358	TH01	D13S317	D16S539	D2S1338	D19S433	vWA	TPOX	D18S51	D5S818	FGA
SIVF023p8	14	30,32.2	11,13	11,13	15,16	9.3	11	11,13	17,24	13,14	14,19	8,9	13,16	11,12	22,24

- Comparative Genomic Hybridisation (CGH) based chromosomal analysis:** Passage 15; CGH was used to screen targeted regions of the genome for gains and losses associated with chromosomal imbalances such as aneuploidy, deletions and duplications. CGH was performed using SurePrint G3 microarrays (8 × 60 K format) which were scanned with the Agilent Scanner C and analysed using Genomic Workbench Standard Edition 5.0 software (Agilent Technologies).
- DNA Profiling:** Passage 8; DNA 'fingerprinting' was performed using the AmpFLSTR Identifier PCR Amplification Kit (Applied Biosystems #4322288) to provide permanent genetic identification of the cell lines. <https://www.thermofisher.com/order/catalog/product/4322288>
- Siblingship testing:** Due to the de-identifying of embryos the siblingship of Genea021, Genea022 and Genea023 was tested at DNA Labs (a subsidiary of Sydney IVF; Sydney, Australia) via analysis of 15 highly variable loci, 15 variable Y chromosome loci and mitochondrial DNA sequences in the D-loop HVRI and HVRII regions.

Pluripotency assessment

- Immunofluorescence:** Passage 14 (11 on feeders, 3 enzymatic); cells were fixed with formalin and stained with Nanog #560483 1:200; Oct4 #560217 1:150; Tra1-60 #560121 1:150; SSEA4 #560308 1:200 (all BD Pharmingen). Images were acquired with an IN Cell Analyser 6000 and quantified using In Cell Developer Software (GE).
- Pluritest:** Passage 14 (11 on feeders, 3 enzymatic); RNA was collected and subjected to a Pluritest, a bioinformatic assay of pluripotency in human cells based on gene expression profiles (Müller et al., 2012).
- Alkaline Phosphatase:** Passage 14; Genea023 grown on feeders were stained as per manufacturers protocol using the Merck Millipore Alkaline Phosphatase Detection Kit (SCR004).
- Teratoma formation:** Passage 41; stem cells were received one day prior to injection. On the day of injection cells were harvested by manual scraping, washed and resuspended in DMEM/20% KSR for intramuscular injection of cells into the left inner thigh muscle of the hind leg. Approximately $1-2 \times 10^6$ cells ($1 \times T25$) in 50 μ L were injected per mouse at one site only. Resultant teratomas were excised, fixed, sectioned and stained for assessment of tissues from each of the embryonic germ layers.

Sterility testing

- Mycoplasma:** Passage 36; testing was performed at the Victorian Infectious Diseases Reference Laboratory using Mycoplasma Genus PCR.
- Microbial contamination:** testing was performed in conjunction with our QC measures. Cells were thawed and cultured in 7 mL antibiotic free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A clear solution at ~48–72 h indicated lack of bacterial, fungal or yeast contamination. Clarity of the solution was assessed by Cell Production Team.

Verification and authentication

Ethics/consents: Karyotyped embryo cells were fully consented for development of stem cells by all responsible people through an informed consent process (signed de-identified consent form can be provided upon request). Donors have received no payment of other

Table 3

Summary of siblingship testing; de-identified Genea021, Genea022 and Genea023 share identical maternal and paternal lines and with variable loci analysis are likely related as full siblings.

	Result
Variable loci analysis	SIVF021 and SIVF022 – full sibs inconclusive SIVF021 and SIVF023 – full sibs practically proven SIVF022 and SIVF023 – full sibs inconclusive
Y chromosome comparison	No mismatches between the lines thus common paternal lineage
Mitochondrial DNA analysis	Identical mitochondrial sequences thus common maternal line
Interpretation	It is likely that all cell lines are related

benefits for their donation. Donated embryos originally created by assisted reproduction technology (ART) for the purpose of procreation. Embryos were identified as unsuitable for implantation, biopsy or freezing due to abnormal development. Embryonic outgrowths were developed for consented clinical investigation studies. Results of the studies have been reported back to the patient.

Morphology: The derived stem cell line, Genea023, morphologically displays adherent monolayer of compact cells in well-defined colonies with high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A).

Genetic analysis: The cell line has been karyotyped (Fig. 1B, Supplementary Fig. 1) and tested by CGH (Table 1, Supplementary Fig. 2), which demonstrated 46, X Y karyotype, consistent with original derivation. Analysis of STR markers showed allele pattern consistent with male genotype (Table 2, Supplementary Fig. 3). Siblingship analysis

showed Genea021 to be siblings with Genea022 and Genea023 (Table 3, Supplementary Fig. 4).

Disease status: Unaffected.

Pluripotency: GENE023 is pluripotent by:

1. Alkaline Phosphatase stain positivity (Fig. 1A).
2. Immunofluorescence with 85% Nanog positive, 98% Oct4, 55% Tra1-60 and 98% SSEA4 positive (Fig. 2A, quantified in 2B).
3. Pluritest with a Pluripotency score of 42.76 and Novelty score of 1.23 (Fig. 2C).
4. Teratoma formation which contained tissues derived from each of the embryonic germ layers: endoderm, mesoderm, and ectoderm (Fig. 2D).

Sterility: The cell line is tested and found negative for *Mycoplasma* and any visible contamination (Supplementary Fig. 5).

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.scr.2016.02.012>.

References

- Amit, M., Carpenter, M.K., Inokuma, M.S., Chiu, C.P., Harris, C.P., Waknitz, M. a, ... Thomson, J. a, 2000. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. *Dev. Biol.* 227 (2), 271–278 <http://doi.org/10.1006/dbio.2000.9912>.
- Bosman, A., Letourneau, A., Sartiani, L., Del Lungo, M., Ronzoni, F., Kuziakiv, R., ... Jaconi, M.E., 2015. Perturbations of heart development and function in cardiomyocytes from human embryonic stem cells with trisomy 21. *Stem Cells* 33 (5), 1434–1446 <http://doi.org/10.1002/stem.1961>.
- Laurent, L.C., Nievergelt, C.M., Lynch, C., Fakunle, E., Harness, J.V., Schmidt, U., ... Loring, J.F., 2010. Restricted ethnic diversity in human embryonic stem cell lines. *Nat. Methods* 7 (1), 5–6. <http://dx.doi.org/10.1038/nmeth0110-6>.




Fig. 2. Pluripotency validation of Genea023. A) Immunofluorescent staining (10×) of pluripotent cell markers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 14, 3 enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest pluripotency (left) and novelty (right) scores with Genea023 (passage 14, 3 enzymatic) outlined in black. D) Tri-lineage teratoma formation (passage 41) with (left) cartilage, bone, squamous epithelium, degenerate neuroepithelium, (right) immature gut epithelium and undifferentiated mesenchyme.

- Laurent, L.C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., ... Loring, J.F., 2011. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. *Cell Stem Cell* 8 (1), 106–118 <http://doi.org/10.1016/j.stem.2010.12.003>.
- McQuade, L., Balachandran, A., 2014. Proteomics of Huntington's disease-affected human embryonic stem cells reveals an evolving pathology involving mitochondrial dysfunction and metabolic disturbances. *J. Proteome* Retrieved from <http://pubs.acs.org/doi/abs/10.1021/pr500649m>.
- Müller, F.-J., Schuldt, B.M., Williams, R., Mason, D., Altun, G., Papapetrou, E., ... Loring, J.F., 2012. A bioinformatic assay for pluripotency in human cells. *Nat. Methods* 8 (4), 315–317. <http://dx.doi.org/10.1038/nmeth.1580.A>.